EP1361892A4 - Binding domain-immunoglobulin fusion proteins - Google Patents
Binding domain-immunoglobulin fusion proteinsInfo
- Publication number
- EP1361892A4 EP1361892A4 EP20020707519 EP02707519A EP1361892A4 EP 1361892 A4 EP1361892 A4 EP 1361892A4 EP 20020707519 EP20020707519 EP 20020707519 EP 02707519 A EP02707519 A EP 02707519A EP 1361892 A4 EP1361892 A4 EP 1361892A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- binding domain
- fusion proteins
- immunoglobulin fusion
- immunoglobulin
- proteins
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 102000037865 fusion proteins Human genes 0.000 title 1
- 108020001507 fusion proteins Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Cell Biology (AREA)
- Transplantation (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13178315.1A EP2706116A1 (en) | 2001-01-17 | 2002-01-17 | Binding domain-immunoglobulin fusion proteins |
EP10182383A EP2316951A1 (en) | 2001-01-17 | 2002-01-17 | Binding domain-immunoglobulin fusion proteins |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US76520801A | 2001-01-17 | 2001-01-17 | |
US765208 | 2001-01-17 | ||
PCT/US2002/001487 WO2002056910A1 (en) | 2001-01-17 | 2002-01-17 | Binding domain-immunoglobulin fusion proteins |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP13178315.1A Division EP2706116A1 (en) | 2001-01-17 | 2002-01-17 | Binding domain-immunoglobulin fusion proteins |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1361892A1 EP1361892A1 (en) | 2003-11-19 |
EP1361892A4 true EP1361892A4 (en) | 2004-10-13 |
Family
ID=25072937
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP13178315.1A Withdrawn EP2706116A1 (en) | 2001-01-17 | 2002-01-17 | Binding domain-immunoglobulin fusion proteins |
EP10182383A Withdrawn EP2316951A1 (en) | 2001-01-17 | 2002-01-17 | Binding domain-immunoglobulin fusion proteins |
EP20020707519 Withdrawn EP1361892A4 (en) | 2001-01-17 | 2002-01-17 | Binding domain-immunoglobulin fusion proteins |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP13178315.1A Withdrawn EP2706116A1 (en) | 2001-01-17 | 2002-01-17 | Binding domain-immunoglobulin fusion proteins |
EP10182383A Withdrawn EP2316951A1 (en) | 2001-01-17 | 2002-01-17 | Binding domain-immunoglobulin fusion proteins |
Country Status (13)
Country | Link |
---|---|
EP (3) | EP2706116A1 (en) |
JP (4) | JP2004525620A (en) |
KR (1) | KR100927261B1 (en) |
CN (3) | CN1911965B (en) |
AU (1) | AU2002241922B2 (en) |
CA (1) | CA2433877C (en) |
IL (2) | IL156955A0 (en) |
MX (1) | MXPA03006358A (en) |
NZ (1) | NZ527591A (en) |
PL (1) | PL364623A1 (en) |
RU (1) | RU2420537C2 (en) |
WO (1) | WO2002056910A1 (en) |
ZA (1) | ZA200305098B (en) |
Families Citing this family (128)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2571230T3 (en) | 1999-04-09 | 2016-05-24 | Kyowa Hakko Kirin Co Ltd | Procedure to control the activity of an immunofunctional molecule |
US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
US7829084B2 (en) * | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
EP1519959B1 (en) | 2002-02-14 | 2014-04-02 | Immunomedics, Inc. | Anti-cd20 antibodies and fusion proteins thereof and methods of use |
US8287864B2 (en) | 2002-02-14 | 2012-10-16 | Immunomedics, Inc. | Structural variants of antibodies for improved therapeutic characteristics |
MXPA05004677A (en) | 2002-10-31 | 2005-11-17 | Genentech Inc | Methods and compositions for increasing antibody production. |
WO2004065417A2 (en) | 2003-01-23 | 2004-08-05 | Genentech, Inc. | Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture |
US7754209B2 (en) | 2003-07-26 | 2010-07-13 | Trubion Pharmaceuticals | Binding constructs and methods for use thereof |
KR20070029733A (en) | 2004-06-04 | 2007-03-14 | 제넨테크, 인크. | Method for treating multiple sclerosis |
US20080181892A1 (en) * | 2004-08-11 | 2008-07-31 | Trubion Pharmaceuticals | Binding Domain Fusion Protein |
EP1959981B1 (en) | 2005-02-03 | 2019-10-16 | Coda Therapeutics Limited | Anti-connexin 43 compounds for treating chronic wounds |
CN105535967B (en) | 2005-02-15 | 2022-05-03 | 杜克大学 | anti-CD 19 antibody and application thereof in oncology |
US8475794B2 (en) | 2005-04-06 | 2013-07-02 | Ibc Pharmaceuticals, Inc. | Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases |
US8349332B2 (en) | 2005-04-06 | 2013-01-08 | Ibc Pharmaceuticals, Inc. | Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases |
AU2006244445B2 (en) | 2005-05-05 | 2013-04-18 | Duke University | Anti-CD19 antibody therapy for autoimmune disease |
US7923538B2 (en) | 2005-07-22 | 2011-04-12 | Kyowa Hakko Kirin Co., Ltd | Recombinant antibody composition |
TWI397536B (en) * | 2005-07-22 | 2013-06-01 | Gene recombination antibodies composition | |
CN100475965C (en) * | 2005-07-22 | 2009-04-08 | 上海高科联合生物技术研发有限公司 | Method for E, coli to express lysostaphin in high efficiency via external secretion |
AU2006272597A1 (en) | 2005-07-25 | 2007-02-01 | Emergent Product Development Seattle Llc | Single dose use of CD20-specific binding molecules |
UA97469C2 (en) | 2005-07-25 | 2012-02-27 | Емерджент Продакт Дівелопмент Сіетл, Елелсі | Humanized cd37-specific binding immunoglobulin molecule |
AR056142A1 (en) * | 2005-10-21 | 2007-09-19 | Amgen Inc | METHODS TO GENERATE THE MONOVALENT IGG ANTIBODY |
MY149159A (en) | 2005-11-15 | 2013-07-31 | Hoffmann La Roche | Method for treating joint damage |
EP1973576B1 (en) * | 2005-11-28 | 2019-05-15 | Genmab A/S | Recombinant monovalent antibodies and methods for production thereof |
CN101351477B (en) | 2005-12-30 | 2011-11-16 | 默克专利有限公司 | Anti-CD19 antibodies with reduced immunogenicity |
PL1966238T3 (en) | 2005-12-30 | 2012-09-28 | Merck Patent Gmbh | Interleukin-12p40 variants with improved stability |
EP1806365A1 (en) | 2006-01-05 | 2007-07-11 | Boehringer Ingelheim International GmbH | Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them |
US7625564B2 (en) * | 2006-01-27 | 2009-12-01 | Novagen Holding Corporation | Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo |
EP2540741A1 (en) | 2006-03-06 | 2013-01-02 | Aeres Biomedical Limited | Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
NZ573646A (en) | 2006-06-12 | 2012-04-27 | Wyeth Llc | Single-chain multivalent binding proteins with effector function |
EP2091557A2 (en) | 2006-11-15 | 2009-08-26 | Coda Therapeutics, INC. | Improved methods and compositions for wound healing |
AU2007336242B2 (en) | 2006-12-19 | 2012-08-30 | Ablynx N.V. | Amino acid sequences directed against GPCRs and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders |
EP2102244A2 (en) | 2006-12-19 | 2009-09-23 | Ablynx N.V. | Amino acid sequences directed against a metalloproteinase from the adam family and polypeptides comprising the same for the treatment of adam-related diseases and disorders |
JP5575636B2 (en) | 2007-05-07 | 2014-08-20 | メディミューン,エルエルシー | Anti-ICOS antibodies and their use in the treatment of tumors, transplants and autoimmune diseases |
ES2565834T3 (en) | 2007-06-01 | 2016-04-07 | University Of Maryland, Baltimore | Immunoglobulin constant region Fc receptor binding agents |
PE20090368A1 (en) | 2007-06-19 | 2009-04-28 | Boehringer Ingelheim Int | ANTI-IGF ANTIBODIES |
BRPI0814465B1 (en) | 2007-07-26 | 2021-11-23 | Novagen Holding Corporation | FUSION PROTEIN, DIMER, METHOD FOR PRODUCING A FUSION PROTEIN, CELL LINEAGE, USES OF A FUSION PROTEIN AND A PHARMACEUTICAL COMPOSITION AND PHARMACEUTICAL COMPOSITION |
CN101970490A (en) | 2007-11-27 | 2011-02-09 | 埃博灵克斯股份有限公司 | Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same |
EP2260058A2 (en) | 2008-04-07 | 2010-12-15 | Ablynx N.V. | Single variable domains against the notch pathways |
NZ603059A (en) | 2008-04-11 | 2014-07-25 | Emergent Product Dev Seattle | Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof |
BRPI0917204A2 (en) | 2008-07-21 | 2015-12-01 | Immunomedics Inc | structural antibody variants for better therapeutic characteristics |
AR073295A1 (en) | 2008-09-16 | 2010-10-28 | Genentech Inc | METHODS TO TREAT PROGRESSIVE MULTIPLE SCLEROSIS. MANUFACTURING ARTICLE. |
MX338825B (en) * | 2008-10-02 | 2016-05-03 | Emergent Product Dev Seattle | Cd86 antagonist multi-target binding proteins. |
PE20110707A1 (en) * | 2008-10-14 | 2011-10-11 | Genentech Inc | IMMUNOGLOBULIN VARIANTS |
AU2009320006A1 (en) | 2008-10-30 | 2010-06-03 | Peixuan Guo | Membrane-integrated viral DNA-packaging motor protein connector biosensor for DNA sequencing and other uses |
CA2743469C (en) | 2008-11-12 | 2019-01-15 | Medimmune, Llc | Antibody formulation |
UA105198C2 (en) | 2008-12-12 | 2014-04-25 | Берингер Ингельхайм Интернациональ Гмбх | Anti-igf antibodies |
WO2010075249A2 (en) | 2008-12-22 | 2010-07-01 | Genentech, Inc. | A method for treating rheumatoid arthritis with b-cell antagonists |
CA2751000A1 (en) | 2009-03-11 | 2010-12-23 | Wyeth Llc | Methods of purifying small modular immunopharmaceutical proteins |
JP5647222B2 (en) | 2009-04-10 | 2014-12-24 | アブリンクス エン.ヴェー. | Improved amino acid sequence directed against IL-6R for the treatment of IL-6R related diseases and disorders and polypeptides comprising the same |
WO2010123119A1 (en) * | 2009-04-23 | 2010-10-28 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Therapeutic agent and screening method for inflammatory bowel disease |
ES2537566T3 (en) * | 2009-06-04 | 2015-06-09 | Novartis Ag | Methods for site identification for IgG conjugation |
DK2438087T3 (en) | 2009-06-05 | 2017-08-28 | Ablynx Nv | TRIVALENT NANOBODY CONSTRUCTIONS AGAINST HUMAN RESPIRATORY SYNCYTIAL VIRUS (HRSV) FOR PREVENTION AND / OR TREATMENT OF AIR INFECTIONS |
US20110195494A1 (en) | 2009-10-02 | 2011-08-11 | Boehringer Ingelheim International Gmbh | Dll4-binging molecules |
UY32920A (en) | 2009-10-02 | 2011-04-29 | Boehringer Ingelheim Int | BISPECIFIC UNION MOLECULES FOR ANTI-ANGIOGENESIS THERAPY |
KR101119995B1 (en) * | 2009-11-10 | 2012-03-16 | 한국기초과학지원연구원 | Screening method of protein-protein interaction inhibitor |
US9644022B2 (en) | 2009-11-30 | 2017-05-09 | Ablynx N.V. | Amino acid sequences directed against human respiratory syncytial virus (HRSV) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections |
WO2011073180A1 (en) | 2009-12-14 | 2011-06-23 | Ablynx N.V. | Single variable domain antibodies against ox40l, constructs and therapeutic use |
EP2516467A2 (en) | 2009-12-23 | 2012-10-31 | Emergent Product Development Seattle, LLC | Compositions comprising tnf-alpha and il-6 antagonists and methods of use thereof |
PT2519543T (en) | 2009-12-29 | 2016-10-07 | Emergent Product Dev Seattle | Heterodimer binding proteins and uses thereof |
WO2011083140A1 (en) | 2010-01-08 | 2011-07-14 | Ablynx Nv | Immunoglobulin single variable domain directed against human cxcr4 |
AR079944A1 (en) | 2010-01-20 | 2012-02-29 | Boehringer Ingelheim Int | NEUTRALIZING ANTIBODY OF THE ACTIVITY OF AN ANTICOAGULANT |
EP2533810B1 (en) | 2010-02-10 | 2016-10-12 | ImmunoGen, Inc. | Cd20 antibodies and uses thereof |
WO2011144749A1 (en) | 2010-05-20 | 2011-11-24 | Ablynx Nv | Biological materials related to her3 |
MX368531B (en) | 2010-07-28 | 2019-10-07 | Gliknik Inc | Fusion proteins of natural human protein fragments to create orderly multimerized immunoglobulin fc compositions. |
ES2603396T3 (en) | 2010-07-30 | 2017-02-27 | Pfizer Inc | Tandem Protein Purification |
WO2012022734A2 (en) | 2010-08-16 | 2012-02-23 | Medimmune Limited | Anti-icam-1 antibodies and methods of use |
GB201014033D0 (en) * | 2010-08-20 | 2010-10-06 | Ucb Pharma Sa | Biological products |
US20120225081A1 (en) | 2010-09-03 | 2012-09-06 | Boehringer Ingelheim International Gmbh | Vegf-binding molecules |
EP3578568A3 (en) | 2010-11-08 | 2020-01-08 | Ablynx N.V. | Cxcr2 binding polypeptides |
JP2014500879A (en) | 2010-11-16 | 2014-01-16 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Factors and methods for treating diseases correlated with BCMA expression |
TWI622597B (en) * | 2011-03-28 | 2018-05-01 | 賽諾菲公司 | Dual variable region antibody-like binding proteins having cross-over binding region orientation |
EP2691156A1 (en) | 2011-03-30 | 2014-02-05 | Boehringer Ingelheim International GmbH | Anticoagulant antidotes |
US9527925B2 (en) | 2011-04-01 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to VEGF and ANG2 |
US20130078247A1 (en) | 2011-04-01 | 2013-03-28 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to dii4 and ang2 |
JP4857396B1 (en) * | 2011-04-13 | 2012-01-18 | 日本製薬株式会社 | Fusion protein |
UA117218C2 (en) | 2011-05-05 | 2018-07-10 | Мерк Патент Гмбх | Amino acid sequences directed against il-17a, il-17f and/or il17-a/f and polypeptides comprising the same |
WO2012162561A2 (en) | 2011-05-24 | 2012-11-29 | Zyngenia, Inc. | Multivalent and monovalent multispecific complexes and their uses |
CA2849765C (en) * | 2011-09-26 | 2021-10-19 | Jn Biosciences Llc | Hybrid constant regions |
US20130122005A1 (en) | 2011-10-27 | 2013-05-16 | Paul Adam | Anticancer combination therapy |
DK2831111T3 (en) | 2012-03-30 | 2019-04-29 | Boehringer Ingelheim Int | Ang2-binding molecules |
BR112014025830A8 (en) | 2012-04-20 | 2017-10-10 | Emergent Product Dev Seattle | CD3-BINDING POLYPEPTIDES |
US9328174B2 (en) | 2012-05-09 | 2016-05-03 | Novartis Ag | Chemokine receptor binding polypeptides |
CA2877986A1 (en) * | 2012-06-27 | 2014-01-03 | Orban Biotech Llc | Ctla4 fusion proteins for the treatment of diabetes |
CN109897115A (en) * | 2012-07-18 | 2019-06-18 | 阿珀吉尼科斯股份公司 | The composition of mixture comprising CD95-Fc isotype |
UA119032C2 (en) * | 2012-10-02 | 2019-04-25 | Женеро Са | Compounds for treating the remyelination blockade in diseases associated with the expression of herv-w envelope protein |
EP2905290B1 (en) | 2012-10-05 | 2019-12-04 | Kyowa Kirin Co., Ltd. | Heterodimeric protein composition |
EP2920210B1 (en) * | 2012-11-19 | 2017-08-30 | Baliopharm AG | Recombinant bispecific antibody binding to cd20 and cd95 |
US20140255413A1 (en) | 2013-03-07 | 2014-09-11 | Boehringer Ingelheim International Gmbh | Combination therapy for neoplasia treatment |
WO2014144600A2 (en) | 2013-03-15 | 2014-09-18 | Viktor Roschke | Multivalent and monovalent multispecific complexes and their uses |
RU2646098C2 (en) | 2013-04-30 | 2018-03-01 | Интас Фармасьютикалс Лтд | New method of cloning, expression and purification for preparation of ranibizumab |
WO2015050959A1 (en) | 2013-10-01 | 2015-04-09 | Yale University | Anti-kit antibodies and methods of use thereof |
CA2931356A1 (en) | 2013-11-27 | 2015-06-04 | Zymeworks Inc. | Bispecific antigen-binding constructs targeting her2 |
NL2013661B1 (en) | 2014-10-21 | 2016-10-05 | Ablynx Nv | KV1.3 Binding immunoglobulins. |
CN107109410B (en) | 2014-08-22 | 2021-11-02 | 奥克兰联合服务有限公司 | Channel modulators |
CN104922670A (en) * | 2015-05-06 | 2015-09-23 | 武汉奥斯梅得生物医药有限公司 | Application of fused immune protein to preparation of medicine for treating multiple sclerosis |
CA2989116A1 (en) * | 2015-06-12 | 2016-12-15 | Ubi Pharma Inc | Immunoglobulin fusion proteins and uses thereof |
US11352426B2 (en) | 2015-09-21 | 2022-06-07 | Aptevo Research And Development Llc | CD3 binding polypeptides |
EP3819310A1 (en) | 2015-10-25 | 2021-05-12 | Sanofi | Trispecific and/or trivalent binding proteins for prevention or treatment of hiv infection |
MY192090A (en) | 2016-04-13 | 2022-07-26 | Sanofi Sa | Trispecific and/or trivalent binding proteins |
WO2017184901A1 (en) * | 2016-04-20 | 2017-10-26 | Fred Hutchinson Cancer Research Center | Immunomodulatory il2r fusion proteins and uses thereof |
LT3458478T (en) | 2016-05-18 | 2021-02-10 | Boehringer Ingelheim International Gmbh | Anti pd-1 and anti-lag3 antibodies for cancer treatment |
EP3464347B1 (en) | 2016-06-07 | 2023-05-31 | Gliknik Inc. | Cysteine-optimized stradomers |
EP3541846A1 (en) | 2016-11-16 | 2019-09-25 | Ablynx NV | T cell recruiting polypeptides capable of binding cd123 and tcr alpha/beta |
US20200368364A1 (en) * | 2016-12-06 | 2020-11-26 | City Of Hope | Cysteine peptide-enabled antibodies |
CN110022898B (en) | 2016-12-09 | 2023-07-04 | 格利克尼克股份有限公司 | Methods of treating inflammatory diseases with multivalent Fc compounds |
US11155574B2 (en) | 2016-12-09 | 2021-10-26 | Gliknik Inc. | Manufacturing optimization of GL-2045, a multimerizing stradomer |
EP3360898A1 (en) | 2017-02-14 | 2018-08-15 | Boehringer Ingelheim International GmbH | Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer |
TW201825515A (en) | 2017-01-04 | 2018-07-16 | 美商伊繆諾金公司 | Met antibodies and immunoconjugates and uses thereof |
EA201892312A1 (en) * | 2017-03-17 | 2019-04-30 | Санофи | TRISPECIFIC AND / OR TRIVALENT BINDING PROTEINS |
US11198726B2 (en) | 2017-06-02 | 2021-12-14 | Boerhinger Ingelheim International Gmbh | Anti-cancer combination therapy |
RU2707535C2 (en) * | 2017-12-28 | 2019-11-27 | Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) | Genetic construct coding structure of t-cell chimeric receptor based on single-chain vhh antibodies specific to tumour receptor cd47 for the targeted immunotherapy of malignant growths |
EP3569618A1 (en) | 2018-05-19 | 2019-11-20 | Boehringer Ingelheim International GmbH | Antagonizing cd73 antibody |
WO2020014306A1 (en) | 2018-07-10 | 2020-01-16 | Immunogen, Inc. | Met antibodies and immunoconjugates and uses thereof |
GB201818477D0 (en) | 2018-11-13 | 2018-12-26 | Emstopa Ltd | Tissue plasminogen activator antibodies and method of use thereof |
CN109679920B (en) * | 2018-12-26 | 2019-11-22 | 北京贝来生物科技有限公司 | A kind of mescenchymal stem cell for expressing IL-17A signal path blocking agent |
US11613576B2 (en) | 2019-04-09 | 2023-03-28 | Sanofi | Trispecific binding proteins, methods, and uses thereof |
CN110305874A (en) * | 2019-06-19 | 2019-10-08 | 浙江省肿瘤医院 | Meriones unguiculatus Immunoglobulin IgG1, IgG2 recombinant protein, gene and its application |
TW202128756A (en) | 2019-10-02 | 2021-08-01 | 德商百靈佳殷格翰國際股份有限公司 | Multi-specific binding proteins for cancer treatment |
CR20220586A (en) | 2020-05-19 | 2023-01-09 | Boehringer Ingelheim Int | Binding molecules for the treatment of cancer |
EP4232474A1 (en) | 2020-10-21 | 2023-08-30 | Boehringer Ingelheim International GmbH | Bispecific anti-vegf and anti-trkb binding molecules for the treatment of eye diseases |
AU2022224636A1 (en) | 2021-02-19 | 2023-09-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Single domain antibodies that neutralize sars-cov-2 |
KR20240019312A (en) * | 2021-06-17 | 2024-02-14 | 파폰 바이오테크 인크. | Chimeric immunoglobulin |
EP4355778A1 (en) | 2021-06-17 | 2024-04-24 | Boehringer Ingelheim International GmbH | Novel tri-specific binding molecules |
US20240052065A1 (en) | 2022-07-15 | 2024-02-15 | Boehringer Ingelheim International Gmbh | Binding molecules for the treatment of cancer |
WO2024083843A1 (en) | 2022-10-18 | 2024-04-25 | Confo Therapeutics N.V. | Amino acid sequences directed against the melanocortin 4 receptor and polypeptides comprising the same for the treatment of mc4r-related diseases and disorders |
WO2024102962A1 (en) | 2022-11-10 | 2024-05-16 | Immuvia Inc | Cytotoxic bispecific antibodies binding to dr5 and muc16 and uses thereof |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992021755A1 (en) * | 1991-05-31 | 1992-12-10 | Genentech, Inc. | Treatment of hiv-associated immune thrombocytopenic purpura |
EP0586002A2 (en) * | 1992-08-18 | 1994-03-09 | CENTRO de IMMUNOLOGIA MOLECULAR | Monoclonal antibodies recognizing the epidermal growth factor receptor, cells and methods for their production and compositions containing them |
WO1994005690A1 (en) * | 1992-09-09 | 1994-03-17 | Smithkline Beecham Corporation | Novel antibodies for conferring passive immunity against infection by a pathogen in humans |
WO1995009917A1 (en) * | 1993-10-07 | 1995-04-13 | The Regents Of The University Of California | Genetically engineered bispecific tetravalent antibodies |
US5736137A (en) * | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
US5776456A (en) * | 1992-11-13 | 1998-07-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
US5844093A (en) * | 1994-03-17 | 1998-12-01 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Anti-EGFR single-chain Fvs and anti-EGFR antibodies |
WO2000044777A1 (en) * | 1999-01-29 | 2000-08-03 | Imclone Systems Incorporated | Antibodies specific to kdr and uses thereof |
Family Cites Families (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US783039A (en) | 1904-04-20 | 1905-02-21 | Fred Hirsh | Clasp. |
US4769330A (en) | 1981-12-24 | 1988-09-06 | Health Research, Incorporated | Modified vaccinia virus and methods for making and using the same |
NZ201418A (en) | 1982-07-28 | 1986-08-08 | Barmac Ass Ltd | Mineral breaker with centrifugal breaking action |
US4737462A (en) | 1982-10-19 | 1988-04-12 | Cetus Corporation | Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β |
US4870009A (en) | 1982-11-22 | 1989-09-26 | The Salk Institute For Biological Studies | Method of obtaining gene product through the generation of transgenic animals |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4518584A (en) | 1983-04-15 | 1985-05-21 | Cetus Corporation | Human recombinant interleukin-2 muteins |
US4745051A (en) | 1983-05-27 | 1988-05-17 | The Texas A&M University System | Method for producing a recombinant baculovirus expression vector |
US5175269A (en) | 1984-01-30 | 1992-12-29 | Enzo Diagnostics, Inc. | Compound and detectable molecules having an oligo- or polynucleotide with modifiable reactive group |
US5118627A (en) | 1984-02-27 | 1992-06-02 | Amgen | Papova virus construction |
US4952496A (en) | 1984-03-30 | 1990-08-28 | Associated Universities, Inc. | Cloning and expression of the gene for bacteriophage T7 RNA polymerase |
US5212286A (en) | 1984-04-19 | 1993-05-18 | Scios Nova Inc. | Atrial natriuretic/vasodilator peptide compounds |
US4719179A (en) | 1984-11-30 | 1988-01-12 | Pharmacia P-L Biochemicals, Inc. | Six base oligonucleotide linkers and methods for their use |
US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
GB8508845D0 (en) | 1985-04-04 | 1985-05-09 | Hoffmann La Roche | Vaccinia dna |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US5869620A (en) | 1986-09-02 | 1999-02-09 | Enzon, Inc. | Multivalent antigen-binding proteins |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US4704692A (en) | 1986-09-02 | 1987-11-03 | Ladner Robert C | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
US5075109A (en) | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
US5187153A (en) | 1986-11-17 | 1993-02-16 | Scios Nova Inc. | Methods of treatment using Alzheimer's amyloid polypeptide derivatives |
US5220013A (en) | 1986-11-17 | 1993-06-15 | Scios Nova Inc. | DNA sequence useful for the detection of Alzheimer's disease |
IL85035A0 (en) * | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
US5229279A (en) | 1987-06-29 | 1993-07-20 | Massachusetts Institute Of Technology | Method for producing novel polyester biopolymers |
US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
US4897268A (en) | 1987-08-03 | 1990-01-30 | Southern Research Institute | Drug delivery system and method of making the same |
WO1989001973A2 (en) | 1987-09-02 | 1989-03-09 | Applied Biotechnology, Inc. | Recombinant pox virus for immunization against tumor-associated antigens |
US5223483A (en) | 1987-10-22 | 1993-06-29 | Merck & Co., Inc. | Cysteine-modified acidic fibroblast growth factor |
JP3095168B2 (en) | 1988-02-05 | 2000-10-03 | エル. モリソン,シェリー | Antibodies with domain-denaturing constants |
US5109124A (en) | 1988-06-01 | 1992-04-28 | Biogen, Inc. | Nucleic acid probe linked to a label having a terminal cysteine |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
JP2752788B2 (en) | 1989-01-23 | 1998-05-18 | カイロン コーポレイション | Recombinant therapy for infection and hyperproliferative disorders |
US5215907A (en) | 1989-02-24 | 1993-06-01 | Oklahoma Medical Research Foundation | Thermostable acid protease from sulfolobus acidocaldarius |
US5173403A (en) | 1989-02-24 | 1992-12-22 | Oklahoma Medical Research Foundation | Thermostable acid protease from sulfolobus acidocaldarius and gene |
US5242687A (en) | 1989-03-15 | 1993-09-07 | Tkb Associates Limited Partnership | Method of reducing cellular immune response involving T-cells using CD8-bearing antigen presenting cells |
US5244805A (en) | 1989-05-17 | 1993-09-14 | University Of Georgia Research Foundation, Inc. | Baculovirus expression vectors |
US5155037A (en) | 1989-08-04 | 1992-10-13 | The Texas A&M University System | Insect signal sequences useful to improve the efficiency of processing and secretion of foreign genes in insect systems |
EP0487587A1 (en) | 1989-08-18 | 1992-06-03 | Chiron Corporation | Recombinant retroviruses delivering vector constructs to target cells |
US5218088A (en) | 1989-11-02 | 1993-06-08 | Purdue Research Foundation | Process for preparing dithiophosphate oligonucleotide analogs via nucleoside thiophosphoramidite intermediates |
US5283173A (en) | 1990-01-24 | 1994-02-01 | The Research Foundation Of State University Of New York | System to detect protein-protein interactions |
AU7444191A (en) | 1990-02-28 | 1991-09-18 | Schering Corporation | Mammalian expression vectors |
KR920003787B1 (en) | 1990-03-05 | 1992-05-14 | 한국과학기술 연구원 | Method for producing igf-i |
US5212058A (en) | 1990-05-09 | 1993-05-18 | Massachusetts Institute Of Technology | Nucleic acid encoding ubiquitin-specific proteases |
US5122463A (en) | 1990-05-17 | 1992-06-16 | Massachusetts Institute Of Technology | Methods for trans-destabilization of specific proteins in vivo and dna molecules useful therefor |
DE4017595A1 (en) | 1990-05-31 | 1991-12-05 | Consortium Elektrochem Ind | MALTOPENTAOSE PRODUCING AMYLASES |
US5169784A (en) | 1990-09-17 | 1992-12-08 | The Texas A & M University System | Baculovirus dual promoter expression vector |
US5266317A (en) | 1990-10-04 | 1993-11-30 | University Of Georgia Research Foundation, Inc. | Insect-specific paralytic neurotoxin genes for use in biological insect control: methods and compositions |
WO1993001286A2 (en) | 1991-06-28 | 1993-01-21 | Massachusetts Institute Of Technology | Localized oligonucleotide therapy |
EP0599850B1 (en) | 1991-08-16 | 1996-01-10 | Vical, Inc. | Composition and method for treating cystic fibrosis |
US5243041A (en) | 1991-08-22 | 1993-09-07 | Fernandez Pol Jose A | DNA vector with isolated CDNA gene encoding metallopanstimulin |
EP0650370A4 (en) | 1992-06-08 | 1995-11-22 | Univ California | Methods and compositions for targeting specific tissue. |
EP0644946A4 (en) | 1992-06-10 | 1997-03-12 | Us Health | Vector particles resistant to inactivation by human serum. |
US5596090A (en) | 1992-07-24 | 1997-01-21 | The United States Of America As Represented By The Secretary Of The Navy | Antisense oligonucleotides directed against human VCAM-1 RNA |
GB2269175A (en) | 1992-07-31 | 1994-02-02 | Imperial College | Retroviral vectors |
US5795572A (en) | 1993-05-25 | 1998-08-18 | Bristol-Myers Squibb Company | Monoclonal antibodies and FV specific for CD2 antigen |
US5571711A (en) | 1993-06-17 | 1996-11-05 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecules coding for BAGE tumor rejection antigen precursors |
DE69533295T3 (en) | 1994-02-16 | 2009-07-16 | The Government Of The United States Of America, As Represented By The Secretary, The Department Of Health And Human Services | Melanoma-associated antigens, epitopes thereof and melanoma-containing vaccines |
US5888773A (en) | 1994-08-17 | 1999-03-30 | The United States Of America As Represented By The Department Of Health And Human Services | Method of producing single-chain Fv molecules |
US5876950A (en) * | 1995-01-26 | 1999-03-02 | Bristol-Myers Squibb Company | Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy |
US5821122A (en) | 1995-06-07 | 1998-10-13 | Inserm (Institute Nat'l De La Sante Et De La Recherche . .) | Isolated nucleic acid molecules, peptides which form complexes with MHC molecule HLA-A2 and uses thereof |
JPH0975090A (en) | 1995-09-13 | 1997-03-25 | Kanegafuchi Chem Ind Co Ltd | Member for adhering cell |
GB9809280D0 (en) * | 1998-04-30 | 1998-07-01 | Rpms Technology Ltd | Immunosupression |
WO2000027885A1 (en) * | 1998-11-05 | 2000-05-18 | Kyowa Hakko Kogyo Co., Ltd. | Novel chimeric polypeptide |
-
2002
- 2002-01-17 CN CN2006100936924A patent/CN1911965B/en not_active Expired - Fee Related
- 2002-01-17 MX MXPA03006358A patent/MXPA03006358A/en active IP Right Grant
- 2002-01-17 CA CA2433877A patent/CA2433877C/en not_active Expired - Fee Related
- 2002-01-17 NZ NZ527591A patent/NZ527591A/en not_active IP Right Cessation
- 2002-01-17 JP JP2002557417A patent/JP2004525620A/en not_active Withdrawn
- 2002-01-17 PL PL02364623A patent/PL364623A1/en not_active Application Discontinuation
- 2002-01-17 RU RU2003125266/10A patent/RU2420537C2/en not_active IP Right Cessation
- 2002-01-17 EP EP13178315.1A patent/EP2706116A1/en not_active Withdrawn
- 2002-01-17 AU AU2002241922A patent/AU2002241922B2/en not_active Ceased
- 2002-01-17 EP EP10182383A patent/EP2316951A1/en not_active Withdrawn
- 2002-01-17 IL IL15695502A patent/IL156955A0/en unknown
- 2002-01-17 CN CNB028038207A patent/CN1268394C/en not_active Expired - Fee Related
- 2002-01-17 WO PCT/US2002/001487 patent/WO2002056910A1/en active Application Filing
- 2002-01-17 KR KR1020037009474A patent/KR100927261B1/en active IP Right Grant
- 2002-01-17 CN CN200910165059A patent/CN101684158A/en active Pending
- 2002-01-17 EP EP20020707519 patent/EP1361892A4/en not_active Withdrawn
-
2003
- 2003-06-30 ZA ZA200305098A patent/ZA200305098B/en unknown
-
2008
- 2008-06-18 JP JP2008159145A patent/JP2008260781A/en not_active Withdrawn
-
2009
- 2009-11-22 IL IL202255A patent/IL202255A0/en unknown
-
2010
- 2010-06-02 JP JP2010126883A patent/JP2010209112A/en active Pending
-
2012
- 2012-11-26 JP JP2012257362A patent/JP2013049707A/en not_active Withdrawn
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992021755A1 (en) * | 1991-05-31 | 1992-12-10 | Genentech, Inc. | Treatment of hiv-associated immune thrombocytopenic purpura |
EP0586002A2 (en) * | 1992-08-18 | 1994-03-09 | CENTRO de IMMUNOLOGIA MOLECULAR | Monoclonal antibodies recognizing the epidermal growth factor receptor, cells and methods for their production and compositions containing them |
WO1994005690A1 (en) * | 1992-09-09 | 1994-03-17 | Smithkline Beecham Corporation | Novel antibodies for conferring passive immunity against infection by a pathogen in humans |
US5736137A (en) * | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
US5776456A (en) * | 1992-11-13 | 1998-07-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
WO1995009917A1 (en) * | 1993-10-07 | 1995-04-13 | The Regents Of The University Of California | Genetically engineered bispecific tetravalent antibodies |
US5844093A (en) * | 1994-03-17 | 1998-12-01 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Anti-EGFR single-chain Fvs and anti-EGFR antibodies |
WO2000044777A1 (en) * | 1999-01-29 | 2000-08-03 | Imclone Systems Incorporated | Antibodies specific to kdr and uses thereof |
Non-Patent Citations (8)
Title |
---|
ANDERSON ET AL: "Targeted anti-cancer therapy using rituximab, a chimeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma", 1997, BIOCHEMICAL SOCIETY TRANSACTIONS, COLCHESTER, ESSEX, GB, PAGE(S) 705-708, ISSN: 0300-5127, XP002078838 * |
GILLILAND L K ET AL: "RAPID AND RELIABLE CLONING OF ANTIBODY VARIABLE REGIONS AND GENERATION OF RECOMBINANT SINGLE CHAIN ANTIBODY FRAGMENTS", 1996, TISSUE ANTIGENS, MUNKSGAARD, COPENHAGEN, DK, PAGE(S) 1-20, ISSN: 0001-2815, XP000574883 * |
HAYDEN M S ET AL: "Single-chain mono- and bispecific antibody derivatives with novel biological properties and antitumour activity from a COS cell transient expression system.", THERAPEUTIC IMMUNOLOGY. ENGLAND JAN 1994, vol. 1, no. 1, January 1994 (1994-01-01), pages 3 - 15, XP009023719, ISSN: 0967-0149 * |
MARTIN S ET AL: "EFFICIENT NEUTRALIZATION AND DISRUPTION OF RHINOVIRUS BY CHIMERIC ICAM-1/IMMUNOGLOBULIN MOLECULES", CIRCULATION RESEARCH, GRUNE AND STRATTON, BALTIMORE, US, vol. 67, no. 6, June 1993 (1993-06-01), pages 3561 - 3568, XP001070889, ISSN: 0009-7330 * |
MUÑOZ E ET AL: "The C(H)1 domain of IgG is not essential for C3 covalent binding: importance of the other constant domains as targets for C3.", INTERNATIONAL IMMUNOLOGY. FEB 1998, vol. 10, no. 2, February 1998 (1998-02-01), pages 97 - 106, XP002288227, ISSN: 0953-8178 * |
PARK S S ET AL: "Generation and characterization of a novel tetravalent bispecific antibody that binds to hepatitis B virus surface antigens.", MOLECULAR IMMUNOLOGY. ENGLAND DEC 2000, vol. 37, no. 18, December 2000 (2000-12-01), pages 1123 - 1130, XP002266827, ISSN: 0161-5890 * |
See also references of WO02056910A1 * |
STEVENSON G T ET AL: "Mechanisms in removal of tumor by antibody.", CELL BIOPHYSICS. 1994, vol. 24-25, 1994, pages 45 - 50, XP009033358, ISSN: 0163-4992 * |
Also Published As
Publication number | Publication date |
---|---|
AU2002241922A2 (en) | 2002-07-30 |
CA2433877A1 (en) | 2002-07-25 |
NZ527591A (en) | 2006-04-28 |
AU2002241922B2 (en) | 2007-10-25 |
CN1268394C (en) | 2006-08-09 |
RU2420537C2 (en) | 2011-06-10 |
JP2010209112A (en) | 2010-09-24 |
CN1911965B (en) | 2013-05-29 |
CN1486192A (en) | 2004-03-31 |
CA2433877C (en) | 2014-11-18 |
IL156955A0 (en) | 2004-02-08 |
IL202255A0 (en) | 2010-06-16 |
ZA200305098B (en) | 2004-09-30 |
EP1361892A1 (en) | 2003-11-19 |
PL364623A1 (en) | 2004-12-13 |
RU2003125266A (en) | 2005-01-20 |
WO2002056910A1 (en) | 2002-07-25 |
CN1911965A (en) | 2007-02-14 |
CN101684158A (en) | 2010-03-31 |
MXPA03006358A (en) | 2004-12-02 |
KR100927261B1 (en) | 2009-11-18 |
EP2706116A1 (en) | 2014-03-12 |
JP2004525620A (en) | 2004-08-26 |
EP2316951A1 (en) | 2011-05-04 |
JP2013049707A (en) | 2013-03-14 |
KR20030066821A (en) | 2003-08-09 |
JP2008260781A (en) | 2008-10-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL202255A0 (en) | Binding domain-immunoglobulin fusion proteins | |
IL161418A0 (en) | Direct targeting binding proteins | |
AU2002364586A8 (en) | Albumin fusion proteins | |
AU2002364587A8 (en) | Albumin fusion proteins | |
EP1365022A4 (en) | Adiponectin-associated protein | |
GB0130557D0 (en) | Proteins | |
GB0130720D0 (en) | Proteins | |
EP1437410A4 (en) | Novel selenocystein-containing proteins | |
GB0200689D0 (en) | Fusion proteins | |
GB0105402D0 (en) | Novel proteins | |
GB0119446D0 (en) | Binding proteins | |
EP1373306A4 (en) | Cytoskeletion-associated proteins | |
AU2003264021A8 (en) | Binding domain-immunoglobulin fusion proteins | |
AU2002326909A8 (en) | Neurotransmission-associated proteins | |
GB0130560D0 (en) | Proteins | |
GB0126888D0 (en) | Binding protein | |
GB0105401D0 (en) | Novel proteins | |
GB0100750D0 (en) | Novel proteins | |
GB0106318D0 (en) | Protein | |
GB0130718D0 (en) | Proteins | |
GB0114313D0 (en) | Proteins | |
GB0120557D0 (en) | Proteins | |
GB0130739D0 (en) | Proteins | |
GB0130743D0 (en) | Proteins | |
GB0125514D0 (en) | Proteins |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20030813 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO SI |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: TRUBION PHARMACEUTICALS, INC. |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: 7C 12N 15/00 B Ipc: 7C 12N 5/10 B Ipc: 7C 12N 15/13 B Ipc: 7C 07K 16/44 B Ipc: 7C 07H 21/04 B Ipc: 7A 61K 39/395 B Ipc: 7C 12N 15/62 A |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20040827 |
|
17Q | First examination report despatched |
Effective date: 20070705 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: EMERGENT PRODUCT DEVELOPMENT SEATTLE, LLC |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1057005 Country of ref document: HK |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20150801 |